MNPRMonopar Therapeutics

Nasdaq monopartx.com


$ 0.69 $ -0.04 (-5.47 %)    

Friday, 10-May-2024 14:57:15 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 0.6722
$ 0.68
$ 0.00 x 0
$ 0.00 x 0
$ 0.68 - $ 0.71
$ 0.27 - $ 1.75
130,782
na
11.75M
$ 0.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 03-26-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-monopar-therapeutics-maintains-2-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $2 price tar...

 monopar-therapeutics-q1-2024-gaap-eps-010-beats-014-estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of ...

 monopar-announces-radiopharma-presentation-selected-for-society-of-nuclear-medicine-and-molecular-imaging-2024-annual-meeting

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments...

 monopar-announces-filing-of-patent-protecting-mnpr-101-radiopharma-optimization-findings

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments...

 jonestrading-upgrades-monopar-therapeutics-to-buy-announces-2-price-target

JonesTrading analyst Soumit Roy upgrades Monopar Therapeutics (NASDAQ:MNPR) from Hold to Buy and announces $2 price target.

 monopar-therapeutics-q4-gaap-eps-012-beats-015-estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of ...

 why-peraso-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...

 monopar-therapeutics-says-nasdaq-has-granted-co-180-day-extension-to-aug-26-to-regain-compliance

-SEC Filing

 monopar-therapeutics-provides-update-on-mnpr-101-zr-radiopharma-clinical-trial-8k

Rradiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar's MNPR-101-Zr Phase 1 dos...

 crude-oil-down-2-maravai-lifesciences-shares-spike-higher

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index jumping more than 100 points on Friday. The ...

 dow-surges-over-150-points-aercap-posts-upbeat-earnings

U.S. stocks traded higher this morning, with the Dow Jones index jumping more than 150 points on Friday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION